Centers for Disease Control and Prevention

West Nile virus vaccine now in phase I clinical trials

Thursday, May 14, 2015 10:48 AM

A novel investigational West Nile virus vaccine discovered and developed by scientists at the Oregon National Primate Research Center at Oregon Health & Science University is being evaluated in an NIH-sponsored phase I, first-in-human, clinical trial at Duke University. Although several early-stage West Nile virus vaccine clinical trials have been completed to date, no human vaccine has been approved for commercial use.

More... »

Quest Diagnostics

Ebola vaccine trial begins in Sierra Leone

Thursday, April 23, 2015 03:08 PM

The Centers for Disease Control and Prevention (CDC), in partnership with the Sierra Leone College of Medicine and Allied Health Sciences (COMAHS) and the Sierra Leone Ministry of Health and Sanitation (MoHS), now is enrolling and vaccinating volunteers for the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE). This study will assess the safety and efficacy of the rVSV-ZEBOV candidate Ebola vaccine among health and other frontline workers.

More... »


NIH funds nine antimicrobial resistance diagnostics projects

Friday, April 10, 2015 01:31 PM

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has awarded more than $11 million in first-year funding for nine research projects supporting enhanced diagnostics to rapidly detect antimicrobial-resistant bacteria. The awardee institutions will develop tools to identify certain pathogens that frequently cause infections in health care settings and, specifically, those that are resistant to most antimicrobials. Advancing the development of rapid and innovative diagnostic tests for identifying and characterizing resistant bacteria is a key goal of the President’s recent National Action Plan for Combating Antibiotic-Resistant Bacteria.

More... »

DARPA awards Inovio $45M Ebola program grant

Thursday, April 9, 2015 01:43 PM

Inovio Pharmaceuticals, based in Plymouth Meeting, Pa., has been awarded a $45 million grant from the Defense Advanced Research Projects Agency (DARPA) to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola.

More... »

Obama administration releases National Action Plan to combat antibiotic-resistant bacteria

Thursday, April 2, 2015 12:59 PM

The White House has released a comprehensive plan that identifies critical actions to be taken by key Federal departments and agencies to combat the rise of antibiotic-resistant bacteria. The National Action Plan for Combating Antibiotic-Resistant Bacteria, which was developed by the interagency Task Force for Combating Antibiotic-Resistant Bacteria in response to Executive Order 13676: Combating Antibiotic-Resistant Bacteria, outlines steps for implementing the plan.

More... »

New Innovative Medicines Initiative project launched to combat carbapenem resistance

Wednesday, March 25, 2015 03:15 PM

Eighteen European academic partners and three pharmaceutical companies are launching a new project under the Innovative Medicines Initiative (IMI) funded New Drugs 4 Bad Bugs (ND4BB) program. COMBACTE-CARE (Combating Bacterial resistance in Europe-Carbapenem-Resistance) will bring highly innovative studies and activities related to the treatment of patients with infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). Being very difficult to treat and sometimes deadly, CRE are considered to be one of the most dangerous resistant bacteria in the world. University Medical Center Utrecht is the project’s managing entity.

More... »

Affinivax, PATH collaborate on pneumococcal disease vaccine candidate

Friday, February 13, 2015 11:30 AM

Affinivax, a Cambridge, Mass.-based biotechnology company dedicated to developing novel vaccines, has entered into a collaboration with PATH, a global health nonprofit organization, to advance the company’s lead vaccine candidate for Streptococcus pneumoniae (pneumococcus). The partnership includes funding from PATH to support product development, preclinical testing and manufacturing, with the goal to qualify and select a final development candidate to advance toward clinical testing.

More... »

Roche, Meiji and Fedora partner to explore bacterial resistance to antibiotics

Wednesday, January 14, 2015 12:38 PM

RocheMeiji Seika Pharma and Fedora have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development. Meiji Seika Pharma is a Japan-based maker of antibacterial drugs. Fedora Pharmaceuticals is headquartered in Edmonton, Alberta, Canada.

More... »

Johnson & Johnson begins phase I clinical trial of Ebola vaccine regimen

Thursday, January 8, 2015 02:19 PM

Johnson & Johnson has begun a phase I, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Pediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.

More... »

Pfizer acquires Redvax

Tuesday, January 6, 2015 09:00 AM

Pfizer has acquired a controlling interest in Redvax, a spinoff from Redbiotec, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs